JP2012514009A5 - - Google Patents

Download PDF

Info

Publication number
JP2012514009A5
JP2012514009A5 JP2011543730A JP2011543730A JP2012514009A5 JP 2012514009 A5 JP2012514009 A5 JP 2012514009A5 JP 2011543730 A JP2011543730 A JP 2011543730A JP 2011543730 A JP2011543730 A JP 2011543730A JP 2012514009 A5 JP2012514009 A5 JP 2012514009A5
Authority
JP
Japan
Prior art keywords
pharmaceutically acceptable
acceptable salt
pharmaceutical composition
compound according
treating
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2011543730A
Other languages
English (en)
Japanese (ja)
Other versions
JP2012514009A (ja
JP5502106B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2009/069852 external-priority patent/WO2010078449A2/en
Publication of JP2012514009A publication Critical patent/JP2012514009A/ja
Publication of JP2012514009A5 publication Critical patent/JP2012514009A5/ja
Application granted granted Critical
Publication of JP5502106B2 publication Critical patent/JP5502106B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2011543730A 2008-12-31 2009-12-30 体液貯留または塩分過負荷と関連する障害および消化管障害の治療におけるnhe媒介性アンチポートを阻害するための組成物および方法 Active JP5502106B2 (ja)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US14185308P 2008-12-31 2008-12-31
US61/141,853 2008-12-31
US16950909P 2009-04-15 2009-04-15
US61/169,509 2009-04-15
US23784209P 2009-08-28 2009-08-28
US61/237,842 2009-08-28
PCT/US2009/069852 WO2010078449A2 (en) 2008-12-31 2009-12-30 Compounds and methods for inhibiting nhe-mediated antiport in the treatment of disorders associated with fluid retention or salt overload and gastrointestinal tract disorders

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2014010049A Division JP5805802B2 (ja) 2008-12-31 2014-01-23 体液貯留または塩分過負荷と関連する障害および消化管障害の治療におけるnhe媒介性アンチポートを阻害するための組成物および方法

Publications (3)

Publication Number Publication Date
JP2012514009A JP2012514009A (ja) 2012-06-21
JP2012514009A5 true JP2012514009A5 (OSRAM) 2014-03-13
JP5502106B2 JP5502106B2 (ja) 2014-05-28

Family

ID=41650053

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2011543730A Active JP5502106B2 (ja) 2008-12-31 2009-12-30 体液貯留または塩分過負荷と関連する障害および消化管障害の治療におけるnhe媒介性アンチポートを阻害するための組成物および方法
JP2014010049A Active JP5805802B2 (ja) 2008-12-31 2014-01-23 体液貯留または塩分過負荷と関連する障害および消化管障害の治療におけるnhe媒介性アンチポートを阻害するための組成物および方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2014010049A Active JP5805802B2 (ja) 2008-12-31 2014-01-23 体液貯留または塩分過負荷と関連する障害および消化管障害の治療におけるnhe媒介性アンチポートを阻害するための組成物および方法

Country Status (22)

Country Link
US (4) US8541448B2 (OSRAM)
EP (3) EP2384318B1 (OSRAM)
JP (2) JP5502106B2 (OSRAM)
KR (5) KR20170091783A (OSRAM)
CN (2) CN103819403B (OSRAM)
AU (1) AU2009334511C1 (OSRAM)
BR (1) BRPI0923861B8 (OSRAM)
CA (1) CA2748607A1 (OSRAM)
CY (1) CY1120451T1 (OSRAM)
DK (1) DK2384318T3 (OSRAM)
ES (1) ES2657938T3 (OSRAM)
HR (1) HRP20180289T1 (OSRAM)
HU (1) HUE036405T2 (OSRAM)
IL (3) IL213852A (OSRAM)
LT (1) LT2384318T (OSRAM)
MX (3) MX345283B (OSRAM)
NO (1) NO2384318T3 (OSRAM)
PL (1) PL2384318T3 (OSRAM)
PT (1) PT2384318T (OSRAM)
SI (1) SI2384318T1 (OSRAM)
SM (1) SMT201800071T1 (OSRAM)
WO (1) WO2010078449A2 (OSRAM)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2384318B1 (en) 2008-12-31 2017-11-15 Ardelyx, Inc. Compounds and methods for inhibiting nhe-mediated antiport in the treatment of disorders associated with fluid retention or salt overload and gastrointestinal tract disorders
WO2018129556A1 (en) * 2017-01-09 2018-07-12 Ardelyx, Inc. Compounds and methods for inhibiting nhe-mediated antiport in the treatment of disorders associated with fluid retention or salt overload and gastrointestinal tract disorders
US10543207B2 (en) 2008-12-31 2020-01-28 Ardelyx, Inc. Compounds and methods for inhibiting NHE-mediated antiport in the treatment of disorders associated with fluid retention or salt overload and gastrointestinal tract disorders
CN102757390B (zh) * 2011-04-27 2015-04-22 中国中化股份有限公司 一种制备2-甲氧基-4-肼基-5-氟嘧啶的方法
US10376481B2 (en) * 2012-08-21 2019-08-13 Ardelyx, Inc. Compounds and methods for inhibiting NHE-mediated antiport in the treatment of disorders associated with fluid retention or salt overload and gastrointestinal tract disorders
HK1211469A1 (en) * 2012-08-21 2016-05-27 Ardelyx, Inc. Compounds and methods for inhibiting nhe-mediated antiport in the treatment of disorders associated with fluid retention or salt overload and gastrointestinal tract disorders
RU2684097C2 (ru) * 2012-08-21 2019-04-04 Эрделикс, Инк. Соединения и способы для ингибирования NHE-опосредованного антипорта в лечении расстройств, ассоциированных с задержкой жидкости или солевой перегрузкой, и заболеваний желудочно-кишечного тракта
NZ752535A (en) * 2013-04-12 2022-08-26 Ardelyx Inc Nhe3-binding compounds and methods for inhibiting phosphate transport
JP2016525508A (ja) 2013-07-02 2016-08-25 ザ カリフォルニア インスティテュート フォー バイオメディカル リサーチ 嚢胞性線維症の処置のための化合物
JP6694385B2 (ja) * 2013-08-09 2020-05-13 アーデリクス,インコーポレーテッド リン酸塩輸送阻害のための化合物及び方法
WO2015084158A1 (en) * 2013-12-06 2015-06-11 N.V. Nutricia A pyrimidine derivative and a fatty acid source for use in the treatment of constipation
PL3173408T3 (pl) * 2014-07-25 2019-05-31 Taisho Pharma Co Ltd Związek fenylotetrahydroizochinolinowy podstawiony heteroarylem
DE102014019388A1 (de) 2014-12-29 2016-06-30 Susanne Wagner Arzneimittel auf der Basis von Maghämit zur gleichzeitigen Reduzierung der gastrointestinalen Natriumresorption und Phosphatresorption
CN107405505A (zh) * 2015-01-07 2017-11-28 加州生物医学研究所 用于治疗囊性纤维化的化合物
JP6421100B2 (ja) * 2015-09-04 2018-11-07 株式会社ダイセル カルボン酸アミド化合物の製造方法
US10016379B2 (en) * 2015-10-30 2018-07-10 Robin L. Webb Method of treatment for third spacing
CN115721729A (zh) * 2016-02-01 2023-03-03 阿拉基斯医疗公司 治疗rna介导的疾病的化合物和方法
WO2018129557A1 (en) * 2017-01-09 2018-07-12 Ardelyx, Inc. Inhibitors of nhe-mediated antiport
WO2018129552A1 (en) * 2017-01-09 2018-07-12 Ardelyx, Inc. Compounds useful for treating gastrointestinal tract disorders
WO2018165520A1 (en) 2017-03-10 2018-09-13 Vps-3, Inc. Metalloenzyme inhibitor compounds
WO2019060051A1 (en) 2017-08-04 2019-03-28 Ardelyx, Inc. GLYCYRRHETINIC ACID DERIVATIVES FOR THE TREATMENT OF HYPERKALIEMIA
EP3705471A4 (en) 2017-11-02 2021-08-11 UBE Industries, Ltd. TWO-HEAD PROTEASE INHIBITOR
WO2019091503A1 (en) 2017-11-13 2019-05-16 Zentiva K.S. Solid forms of tenapanor and method of preparation of tenapanor
CN109897044A (zh) * 2017-12-07 2019-06-18 北京大学 抗神经病理性疼痛化合物及其制备方法
WO2020051014A1 (en) 2018-09-04 2020-03-12 Teva Pharmaceuticals International Gmbh Processes for the preparation of tenapanor and intermediates thereof
CN109321529A (zh) * 2018-10-19 2019-02-12 浙江工商大学 一种体外肠道模型的构建方法和应用
PH12021551892A1 (en) 2019-02-07 2022-08-01 Ardelyx Inc Glycyrrhetinic acid derivatives for use in treating hyperkalemia
WO2020181555A1 (zh) * 2019-03-14 2020-09-17 深圳仁泰医药科技有限公司 Nhe3抑制剂的晶型a及其制备方法和应用
JP7194848B2 (ja) 2019-05-16 2022-12-22 イーライ リリー アンド カンパニー ナトリウム-水素交換体3阻害剤化合物
JP2022533251A (ja) 2019-05-21 2022-07-21 アルデリックス, インコーポレイテッド 患者において血清リン酸塩を低下させるための組み合わせ
CN112679427B (zh) * 2019-10-17 2023-05-12 江苏恒瑞医药股份有限公司 四氢异喹啉类衍生物、其制备方法及其在医药上的应用
CN111217490B (zh) * 2019-12-30 2024-09-06 北京航天环境工程有限公司 一种轻型填料的双层生物滤池系统和应用
BR112023002132A2 (pt) * 2020-08-04 2023-04-11 Sigilon Therapeutics Inc Compostos de heteroarila e heterociclila
CN112047881B (zh) * 2020-10-10 2023-04-11 山东汇海医药化工有限公司 一种坦帕诺的制备方法
EP4265608A4 (en) * 2020-12-18 2024-12-11 Shanghai Jemincare Pharmaceuticals Co., Ltd. Benzoheterocycle substituted tetrahydroisoquinoline compound
CN114805202A (zh) * 2021-01-28 2022-07-29 江西济民可信集团有限公司 苯磺酰胺类化合物及其制备方法和应用
TWI842576B (zh) * 2022-06-20 2024-05-11 大陸商上海濟煜醫藥科技有限公司 苯並雜環取代四氫異喹啉類化合物鹽型及其製備方法
CN116284240A (zh) * 2023-04-04 2023-06-23 江苏大学 一种仿生类肽防冰抗冻剂及其制备方法和应用

Family Cites Families (130)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3926891A (en) 1974-03-13 1975-12-16 Dow Chemical Co Method for making a crosslinkable aqueous solution which is useful to form soft, water-swellable polyacrylate articles
US3935099A (en) 1974-04-03 1976-01-27 The United States Of America As Represented By The Secretary Of Agriculture Method of reducing water content of emulsions, suspensions, and dispersions with highly absorbent starch-containing polymeric compositions
US3997484A (en) 1974-04-03 1976-12-14 The United States Of America As Represented By The Secretary Of Agriculture Highly-absorbent starch-containing polymeric compositions
US4090013A (en) 1975-03-07 1978-05-16 National Starch And Chemical Corp. Absorbent composition of matter
JPS51125468A (en) 1975-03-27 1976-11-01 Sanyo Chem Ind Ltd Method of preparing resins of high water absorbency
JPS5346389A (en) 1976-10-07 1978-04-25 Kao Corp Preparation of self-crosslinking polymer of acrylic alkali metal salt
US4190562A (en) 1977-04-04 1980-02-26 The B. F. Goodrich Company Improved water absorbent copolymers of copolymerizable carboxylic acids and acrylic or methacrylic esters
US4470975A (en) 1977-10-21 1984-09-11 The Johns Hopkins University Method and composition for the elimination of water from an animal body
US4286082A (en) 1979-04-06 1981-08-25 Nippon Shokubai Kagaku Kogyo & Co., Ltd. Absorbent resin composition and process for producing same
JPS6025045B2 (ja) 1980-03-19 1985-06-15 製鉄化学工業株式会社 塩水吸収能のすぐれたアクリル酸重合体の製造方法
JPS57158209A (en) 1981-03-25 1982-09-30 Kao Corp Production of bead-form highly water-absorbing polymer
JPS5832607A (ja) 1981-08-20 1983-02-25 Kao Corp 吸水性に優れた吸水材料の製造法
US4985518A (en) 1981-10-26 1991-01-15 American Colloid Company Process for preparing water-absorbing resins
JPS6187702A (ja) 1984-10-05 1986-05-06 Seitetsu Kagaku Co Ltd 吸水性樹脂の製造方法
US4708997A (en) 1985-07-22 1987-11-24 The Dow Chemical Company Suspending agent for the suspension polymerization of water-soluble monomers
US4806532A (en) 1985-10-08 1989-02-21 Mayo Foundation For Medical Education And Research Inhibition of epithelial phosphate transport
DE3544770A1 (de) 1985-12-18 1987-06-19 Stockhausen Chem Fab Gmbh Verfahren und vorrichtung zum kontinuierlichen herstellen von polymerisaten und copolymerisaten der acrylsaeure und/oder methacrylsaeure
US4766004A (en) 1986-12-19 1988-08-23 Warner-Lambert Company Crunchy, highly palatable, bulk-increasing, dietary fiber supplement composition
IT1217123B (it) 1987-02-05 1990-03-14 Rotta Research Lab Derivati otticamente attivi dell acido 5 pentilammino 5 oxo pentanoico r ad attivita antagonista della colecistochinina e procedimento per la loro preparazione
US4999200A (en) 1987-12-09 1991-03-12 Marion Laboratories Psyllium tablet composition, method of manufacture and method of use
US5149541A (en) 1988-10-03 1992-09-22 The Procter & Gamble Company Psyllium-containing produces with a distribution of particle size
US5145906A (en) 1989-09-28 1992-09-08 Hoechst Celanese Corporation Super-absorbent polymer having improved absorbency properties
US5126150A (en) 1990-10-01 1992-06-30 The Procter & Gamble Company Compositions containing psyllium
HUT64023A (en) 1991-03-22 1993-11-29 Sandoz Ag Process for producing aminoguanidine derivatives and pharmaceutical compositions comprising such compounds
FR2674849B1 (fr) 1991-04-02 1994-12-23 Logeais Labor Jacques Nouveaux derives de n-cyclohexyl benzamides ou thiobenzamides, leurs preparations et leurs applications en therapeutique.
US5140102A (en) 1991-09-23 1992-08-18 Monsanto Company Pentadecapeptide, guanylin, which stimulates intestinal guanylate cyclase
US5824645A (en) 1991-12-30 1998-10-20 Neurex Corporation Method of treating inflammation
AU689438B2 (en) 1991-12-30 1998-04-02 Azur Pharma International Limited Methods of producing analgesia and enhancing opiate analgesia
US5969097A (en) 1992-06-23 1999-10-19 G. D. Searle & Co. Human guanylin
ATE157351T1 (de) 1993-02-20 1997-09-15 Hoechst Ag Substituierte benzoylguanidine, verfahren zu ihrer herstellung, ihre verwendung als medikament, als inhibitoren des zellulären na+/h+-austauschs oder als diagnostikum sowie sie enthaltendes medikament
MX213505B (OSRAM) 1993-02-24 2003-04-03
US5629377A (en) 1993-03-10 1997-05-13 The Dow Chemical Company Water absorbent resin particles of crosslinked carboxyl containing polymers and method of preparation
IL109570A0 (en) 1993-05-17 1994-08-26 Fujisawa Pharmaceutical Co Guanidine derivatives, pharmaceutical compositions containing the same and processes for the preparation thereof
US5489670A (en) 1993-10-29 1996-02-06 G. D. Searle & Co. Human uroguanylin
US5610145A (en) 1994-04-15 1997-03-11 Warner-Lambert Company Tachykinin antagonists
US5650222A (en) 1995-01-10 1997-07-22 The Procter & Gamble Company Absorbent foam materials for aqueous fluids made from high internal phase emulsions having very high water-to-oil ratios
DE19518796A1 (de) 1995-05-22 1996-11-28 Hoechst Ag Fluorphenylsubstituierte Alkenylcarbonsäure-guanidine, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament oder Diagnostikum sowie sie enthaltendes Medikament
DE69627153T2 (de) 1995-06-27 2003-12-04 Elan Pharmaceuticals, Inc.(N.D.Ges.D.Staates Delaware) Zusammensetzungen zur erzielung von analgesie und zur hemmung der progression neuropathischer schmerzerkrankungen
US5795864A (en) 1995-06-27 1998-08-18 Neurex Corporation Stable omega conopetide formulations
US6054429A (en) 1996-03-08 2000-04-25 Elan Pharmaceuticals, Inc. Epidural method of producing analgesia
US5550167A (en) 1995-08-30 1996-08-27 The Procter & Gamble Company Absorbent foams made from high internal phase emulsions useful for acquiring aqueous fluids
CZ157998A3 (cs) 1995-11-24 1998-12-16 Smithkline Beecham S. P. A. Chinolinové deriváty, způsob jejich přípravy, farmaceutický prostředek a použití
GB9524104D0 (en) 1995-11-24 1996-01-24 Smithkline Beecham Spa Novel compounds
DE19548812A1 (de) 1995-12-27 1997-07-03 Hoechst Ag Verwendung von Inhibitoren des zellulären Na·+·/H·+·-Exchangers (NHE) zur Herstellung eines Medikaments zur Atemstimulation
EP0837055A1 (en) 1996-07-30 1998-04-22 Hoechst Aktiengesellschaft Substituted Indanylidineacetylguanidines, process for their preparation, their use as medicaments or diagnostic and medicaments containing them
DE19633966A1 (de) 1996-08-22 1998-02-26 Hoechst Ag Phenylsubstituierte Alkenylcarbonsäure-guanidine, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament oder Diagnostikum sowie sie enthaltendes Medikament
AU4176997A (en) 1996-09-16 1998-04-02 Warner-Lambert Company 3-alkyl-3-phenyl-piperidines
SI0975347T1 (sl) 1997-02-28 2008-08-31 Nycomed Gmbh Sinergistična kombinacija PDE inhibitorjev in agonistov adenilat ciklaze oziroma agonistov gvanil ciklize
NZ329807A (en) 1997-04-23 2000-07-28 Pfizer NK-1 receptor antagonists and P receptor antagonists 2-Diarylmethyl-3-amino-1-azabicyclo[2.2.2]octane derivatives and amino substituted N-containing rings as agents for treating irritable bowel syndrome
KR100219918B1 (ko) 1997-07-03 1999-09-01 김윤 대장선택적 약물전달용 조성물
US20010006972A1 (en) 1998-04-21 2001-07-05 Stephen A. Williams Nk-1 receptor antagonists for the treatment of symptoms of irritable bowel syndrome
KR20000011247A (ko) 1998-07-23 2000-02-25 김윤 다당류를이용한대장선택성약물전달조성물및약학제제
DE19849722A1 (de) 1998-10-28 2000-05-04 Aventis Pharma Gmbh Substituierte Phenyl-alkenoylguanidine, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament oder Diagnostikum sowie sie enthaltendes Medikament
CA2371910A1 (en) 1999-01-21 2000-07-27 Brian E. Peerce Inhibitors of intestinal apical membrane na/phosphate co-transportation
US6624150B2 (en) 1999-02-26 2003-09-23 Inspire Pharmaceuticals, Inc. Method of treating gastrointestinal tract disease with purinergic receptor agonists
US6287609B1 (en) 1999-06-09 2001-09-11 Wisconsin Alumni Research Foundation Unfermented gel fraction from psyllium seed husks
EP1196396B1 (en) 1999-07-19 2008-03-26 University Of North Carolina At Chapel Hill Pharmacologically active compounds with two covalently linked active principles (sodium channnel blocker/p2y2 receptor agonist) for the treatment of mucosal surfaces
CO5190714A1 (es) 1999-07-20 2002-08-29 Smithkline Beecham Corp Inhibidores del transporte de fosfato
US6107356A (en) 1999-08-23 2000-08-22 The Procter & Gamble Company High suction polymeric foam materials
DE19941764A1 (de) * 1999-09-02 2001-03-15 Aventis Pharma Gmbh Substituierte Acylguanidine, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikamente oder Diagnostika sowie sie enthaltende Medikamente
SE9903291D0 (sv) 1999-09-15 1999-09-15 Astra Ab New process
DE19945302A1 (de) 1999-09-22 2001-03-29 Merck Patent Gmbh Biphenylderivate als NHE-3-Inhibitoren
US6887870B1 (en) 1999-10-12 2005-05-03 Bristol-Myers Squibb Company Heterocyclic sodium/proton exchange inhibitors and method
CZ299726B6 (cs) 1999-11-01 2008-11-05 Lécivo pro lécení zácpy a syndromu dráždivého tracníku
AUPQ514600A0 (en) 2000-01-18 2000-02-10 James Cook University Brain injury treatment
WO2001064212A1 (en) 2000-03-01 2001-09-07 University College London Modulators of the endocannabinoid uptake and of the vallinoid receptors
DE10015248A1 (de) 2000-03-28 2001-10-04 Merck Patent Gmbh Bisamidino-Verbindungen als NHE-3 Inhibitoren
DE10019062A1 (de) 2000-04-18 2001-10-25 Merck Patent Gmbh 2-Guanidino-4-aryl-chinazoline als NHE-3 Inhibitoren
US20030212074A1 (en) 2000-05-02 2003-11-13 Dimitri Gaitanopoulos Phosphate transport inhibitors
AU2001261471A1 (en) 2000-05-12 2001-11-26 Smithkline Beecham Corporation Phosphate transport inhibitors
DE10043667A1 (de) 2000-09-05 2002-03-14 Merck Patent Gmbh 2-Guanidino-4-aryl-chinazoline
US6414016B1 (en) 2000-09-05 2002-07-02 Sucampo, A.G. Anti-constipation composition
DE10046993A1 (de) 2000-09-22 2002-04-11 Aventis Pharma Gmbh Substituierte Zimtsäureguanidide, Verfahren zur ihrer Herstellung, ihre Verwendung als Medikament sowie sie enthaltendes Medikament
WO2002028353A2 (en) 2000-10-05 2002-04-11 Smithkline Beecham Corporation Phosphate transport inhibitors
EP2324861A1 (en) 2000-11-20 2011-05-25 Sorbent Therapeutics, Inc. In vivo use of water absorbent polymers
DE10063294A1 (de) 2000-12-19 2002-07-04 Aventis Pharma Gmbh Substituierte Heterocyclo-Norbornylamino-Derivate, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament oder Diagnostikum sowie sie enthaltendes Medikament
JP4206272B2 (ja) 2001-03-29 2009-01-07 サイナージィ ファーマスーティカルズ、インコーポレイテッド 組織炎症及び発癌を治療するためのグアニル酸シクラーゼ受容体アゴニスト
US6736705B2 (en) 2001-04-27 2004-05-18 Hitachi Global Storage Technologies Polishing process for glass or ceramic disks used in disk drive data storage devices
MY134211A (en) 2001-05-18 2007-11-30 Smithkline Beecham Corp Novel use
JP2007131532A (ja) 2001-09-28 2007-05-31 Kirin Brewery Co Ltd 生体内リン輸送を阻害する化合物およびそれを含んでなる医薬
FR2830451B1 (fr) 2001-10-09 2004-04-30 Inst Nat Sante Rech Med Utilisation de peptides analogues de la thymuline(pat)pour la fabrication de medicaments contre la douleur
DK1453810T3 (da) * 2001-12-05 2009-07-20 Sanofi Aventis Deutschland Substituerede 4-phenyltetrahydroisoquinoliner, fremgangsmåde til deres fremstilling, deres anvendelse som medikament indeholdende samme
JPWO2003048134A1 (ja) 2001-12-05 2005-04-14 日本たばこ産業株式会社 トリアゾール化合物及びその医薬用途
US6911453B2 (en) 2001-12-05 2005-06-28 Aventis Pharma Deutschland Gmbh Substituted 4-phenyltetrahydroisoquinolinium, process for their preparation, their use as a medicament, and medicament containing them
DE10161767A1 (de) 2001-12-15 2003-06-26 Merck Patent Gmbh 2-Guanidino-4-heterocyclyl-chinazoline
EP1321142A1 (en) 2001-12-21 2003-06-25 Novartis AG Solid pharmaceutical composition for oral administration of Tegaserod
DE10163914A1 (de) * 2001-12-22 2003-07-03 Aventis Pharma Gmbh Substituierte 4-Phenyltetrahydroisochinolinium-Salze, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament, sowie sie enthaltendes Medikament
US6703405B2 (en) 2001-12-22 2004-03-09 Aventis Pharma Deutschland Gmbh Substituted 4-phenyltetrahydroisoquinolinium salts, process for their preparation, their use as a medicament, and medicament containing them
DE10163992A1 (de) 2001-12-24 2003-07-03 Merck Patent Gmbh 4-Aryl-chinazoline
US7119120B2 (en) 2001-12-26 2006-10-10 Genzyme Corporation Phosphate transport inhibitors
ES2399880T3 (es) 2002-03-15 2013-04-04 Cypress Bioscience, Inc. Milnaciprán para el tratamiento del síndrome del intestino irritable
US7109184B2 (en) 2002-03-19 2006-09-19 Genzyme Corporation Phosphate transport inhibitors
EP1505974B1 (en) 2002-05-17 2009-04-22 Tioga Pharmaceuticals, Inc. Use of compounds that are effective as selective opiate receptor modulators
US7014862B2 (en) 2002-05-20 2006-03-21 The Procter & Gamble Company Chewable compositions containing a gel-forming extract of psyllium
TWI245308B (en) 2002-09-13 2005-12-11 Getters Spa Non-evaporable getter compositions which can be reactivated at low temperature after exposure to reactive gases at a higher temperature
CN1254051C (zh) 2002-10-25 2006-04-26 华为技术有限公司 城域网传输设备中用户数据业务子速率传送方法
US6923466B2 (en) 2002-12-17 2005-08-02 James Tsai Collapsible handcart capable of extending the area of carrier by operating handle
US7304036B2 (en) 2003-01-28 2007-12-04 Microbia, Inc. Methods and compositions for the treatment of gastrointestinal disorders
US20050054705A1 (en) 2003-02-04 2005-03-10 Aventis Pharma Deutschland Gmbh N-substituted (benzoimidazol-2-yl) phenylamines, process for their preparation, their use as medicament or diagnostic aid, and medicament comprising them
US7026303B2 (en) 2003-02-18 2006-04-11 The Procter & Gamble Company Compositions comprising a polysaccharide component and one or more coating layers
WO2004085448A2 (en) 2003-03-19 2004-10-07 Genzyme Corporation Unsaturated phosphinyl-phosphonate phosphate transport inhibitors
DE10312963A1 (de) * 2003-03-24 2004-10-07 Aventis Pharma Deutschland Gmbh Substituierte 4-Phenyltetrahydroisochinoline, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament, sowie sie enthaltendes Medikament
US7241775B2 (en) 2003-03-24 2007-07-10 Sanofi-Aventis Deutschland Gmbh Composition, process of making, and medical use of substituted 4-phenyltetrahydroisoquinolines
EP1614676A4 (en) 2003-03-27 2009-03-25 Kirin Pharma Kk CONNECTION TO INHIBITING IN VIVO PHOSPHORUS TRANSPORT AND MEDICAMENT CONTAINING THEREOF
US8338074B2 (en) 2003-06-25 2012-12-25 Cmet Inc. Actinic radiation-curable stereolithographic resin composition having improved stability
WO2005020612A1 (en) 2003-08-20 2005-03-03 Musky Communications (Proprietary) Limited Telephonic communication
PE20050952A1 (es) * 2003-09-24 2005-12-19 Novartis Ag Derivados de isoquinolina como inhibidores de b-raf
US20050095578A1 (en) 2003-10-31 2005-05-05 Koller Manfred R. Method and apparatus for cell permeabilization
WO2005054705A2 (en) 2003-11-26 2005-06-16 Brian Judd Apparatus for dampening impact vibration in manual tools
US20050244367A1 (en) 2004-05-03 2005-11-03 Ilypsa, Inc. Phospholipase inhibitors localized in the gastrointestinal lumen
CN1984668A (zh) 2004-05-14 2007-06-20 北卡罗来纳大学查珀尔希尔分校 作为涉及盐和/或体液稳态的疾病的治疗剂和诊断剂的尿鸟苷蛋白原及合成的类似物或自其衍生的蛋白酶解产物
CN101427212A (zh) 2004-05-14 2009-05-06 佩斯科股份有限公司 用于制造集装箱装卸机的状态报告装置的方法和设备
DE102004046492A1 (de) * 2004-09-23 2006-03-30 Sanofi-Aventis Deutschland Gmbh Substituierte 4-Phenyltetrahydroisochinoline, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament, sowie sie enthaltendes Medikament
US20070054916A1 (en) * 2004-10-01 2007-03-08 Amgen Inc. Aryl nitrogen-containing bicyclic compounds and methods of use
CN101040028B (zh) 2004-10-13 2012-03-28 罗利克有限公司 光可交联材料
DE102004054847A1 (de) 2004-11-13 2006-05-24 Sanofi-Aventis Deutschland Gmbh Substituierte Benzoylguanidine, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament oder Diagnostikum sowie sie enthaltendes Medikament
DE102005001411A1 (de) * 2005-01-12 2006-07-27 Sanofi-Aventis Deutschland Gmbh Substituierte 4-Phenyltetrahydroisochinoline, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament, sowie sie enthaltendes Medikament
US8505649B2 (en) 2005-08-29 2013-08-13 Demain Technology Pty Ltd. Power tool
DE102005044817A1 (de) 2005-09-20 2007-03-22 Sanofi-Aventis Deutschland Gmbh Substituierte 4-Phenyltetrahydroisochinoline, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament, sowie sie enthaltendes Medikament
DE102005044815A1 (de) 2005-09-20 2007-03-22 Sanofi-Aventis Deutschland Gmbh Verwendung von Inhibitoren des Na+/H+ Austauschers, Subtyp 5 (NHE5) zur Gedächtnisverbesserung
US20070135383A1 (en) 2005-11-03 2007-06-14 Han-Ting Chang Phospholipase inhibitors, including multi-valent phospholipase inhibitors, and use thereof, including as lumen-localized phospholipase inhibitors
AU2006311767A1 (en) 2005-11-03 2007-05-18 Ilypsa, Inc. Multivalent indole compounds and use thereof as phospholipase-A2 inhibitors
US7694181B2 (en) 2005-12-12 2010-04-06 Archivas, Inc. Automated software testing framework
GB0610009D0 (en) 2006-05-19 2006-06-28 Health Prot Agency Culture medium
GB2438389A (en) 2006-05-23 2007-11-28 Gkn Aerospace Transparency Sys Heating system for leading edge of aircraft
US20120283411A9 (en) 2006-06-29 2012-11-08 Ironwood Pharmaceuticals, Inc. Methods and compositions for the treatment of gastrointestinal disorders
US8617903B2 (en) 2007-01-29 2013-12-31 The Invention Science Fund I, Llc Methods for allergen detection
US8779090B2 (en) 2007-02-26 2014-07-15 Ironwood Pharmaceuticals, Inc. Methods and compositions for the treatment of heart failure and other disorders
EP2671584A3 (en) 2007-05-04 2014-03-26 Ironwood Pharmaceuticals, Inc. Compositions and methods for treating disorders associated with salt or fluid retention
EP2384318B1 (en) 2008-12-31 2017-11-15 Ardelyx, Inc. Compounds and methods for inhibiting nhe-mediated antiport in the treatment of disorders associated with fluid retention or salt overload and gastrointestinal tract disorders

Similar Documents

Publication Publication Date Title
JP2012514009A5 (OSRAM)
JP2011105738A5 (OSRAM)
JP2012107057A5 (OSRAM)
JP2009502793A5 (OSRAM)
JP2007269812A5 (OSRAM)
JP2013532130A5 (OSRAM)
JP2009535462A5 (OSRAM)
JP2013525444A5 (OSRAM)
JP2010501534A5 (OSRAM)
JP2014520248A5 (OSRAM)
JP2011510079A5 (OSRAM)
JP2013532687A5 (OSRAM)
JP2011508438A5 (OSRAM)
RU2582676C3 (ru) Некоторые химические соединения, композиции и способы
JP2009536652A5 (OSRAM)
JO3757B1 (ar) التركيبات الصيدلانية التي تشمل على نيلوتينيب أو أملاحه
MX363056B (es) Compuestos y metodos para inhibir al antipuerto mediado por nhe en el tratamiento de trastornos asociados con la retencion de fluidos o la sobrecarga de sal y trastornos del tracto gastrointestinal.
JP2007522220A5 (OSRAM)
BRPI0910734A2 (pt) composto, composição farmacêutica, e, processo para preparar um composto ou um sal farmaceuticamente aceitável do mesmo.
JP2006298933A5 (OSRAM)
JP2011527299A5 (OSRAM)
JP2011519871A5 (OSRAM)
JP2011037885A5 (OSRAM)
HK1211469A1 (en) Compounds and methods for inhibiting nhe-mediated antiport in the treatment of disorders associated with fluid retention or salt overload and gastrointestinal tract disorders
JP2009537554A5 (OSRAM)